RespireRx Pharmaceuticals (OTC:RSPI) said a case study demonstrating positive results from the treatment of an epilepsy patient involving its therapeutic KRM-II-81 has been published in a peer-reviewed journal.
The company said that the 19-year-old patient in the case study had pharmaco-resistant epilepsy and required a craniotomy to remove the brain tissue generating seizures.
Cortical brain tissue surgically resected from the patient exhibited epileptiform bursting with microelectrode recordings but once KRM–II–81, one of RespireRX’s GABAkines, was added to the incubation fluid, the epileptiform activity in the excised brain tissue was fully suppressed, the company highlighted.
A year after the surgery, the patient remains seizure-free but on medication.
“Although our research team has observed suppression of activity previously in cortical tissue from epileptic patients, we have now observed recurrent epileptiform bursting in this patient’s tissue,” explained case study lead researcher Dr. Jodi Smith, director of pediatric neurosurgery Peyton Manning Children’s Hospital at Ascension St. Vincent Medical in Indianapolis.
Corresponding author and senior research fellow with RespireRX Rok Cerne added: “The complete abolishment of these epileptic bursts by our GABAkine is one of the most impressive demonstrations we have made to date with KRM-II-81.”
“The data are highly encouraging for us to continue with Investigational New Drug (IND)-enabling animal studies conducted in collaboration with the National Institutes of Health and to move into the clinic with KRM-II-81.”
“KRM-II-81 fully suppressed the epileptiform bursting, which returned when KRM-II-81 was removed from the incubation medium. We feel that this observation is an impressive indicator for success in translation to patient treatment for this compound.”
The case study was published in Heliyon, Cell Press’s peer-reviewed journal.
RespireRx Pharmaceuticals (OTC:RSPI) and its subsidiaries and business units are discovering and developing medicines for the treatment of psychiatric and neurological disorders, with a focus on treatments that address conditions affecting millions of people, but for which there are few or poor treatment options, including epilepsy, pain, attention deficit hyperactivity disorder, recovery from spinal cord injury, certain neurological orphan diseases and obstructive sleep apnea.